Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.
Relapsed/Refractory Leukemias
DRUG: SGI-1776
The MTD as determined by the incidence of DLTs in the first 4 weeks of each dosing cohort, July 2011
• Frequency, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs) •, 1 year
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects with Relapsed/Refractory Leukemias